Pharmacokinetics of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children in the ARROW trial.
- Department for International Development
- 1 January 2009
- Document Type:
- Conference Paper
- Walker, A.S., Mugyenyi, P., Nahirya-Ntege, P., Nathoo, K.J., Kekitiinwa, A. Musiime, V., Musoke, P., Ferrier, A., Kitaka, S.B., Odongo, F., Thomason, M.J., Lee, D.Y., Burger, D., Thoofer, N., and Snowden, W.
41 HIV-infected children in Uganda, not previously treated with antiretroviral drugs, were treated with twice-daily lamivudine and abacavir for 36 weeks, and the pharmacokinetics of both drugs in the blood was studied over a 12-hour period following that day's dose. The children were then switched to a once-daily regimen for 4 weeks, and a similar pharmacokinetic investigation (with an additional sample 24 hours post-dose) was done. For both drugs, the area under the concentration-time curve was similar in the twice-daily and once-daily regimens; the maximum concentration was 76% and 64% higher for lamivudine and abacavir respectively under the once-daily regimen. Most of the patients and their caregivers preferred the once-daily regimen which, it is concluded, appears to be a feasible alternative to the twice-daily regimen.
Musiime, V.; Ferrier, A.; Kitaka, S.B.; Odongo, F.; Kekitiinwa, A.; Thomason, M.J.; Lee, D.Y.; Burger, D.; Thoofer, N.; Nahirya-Ntege, P.; Nathoo, K.J.; Snowden, W.; Musoke, P.; Mugyenyi, P.; Walker, A.S. Pharmacokinetics of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children in the ARROW trial. Presented at 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, and 1st International Workshop on HIV Pediatrics, 17-18 July 2009, Cape Town, South Africa. (2009)
Published: 1 January 2009
Document Type: Conference Paper
Authors: Walker, A.S. Mugyenyi, P. Nahirya-Ntege, P. Nathoo, K.J. Kekitiinwa, A. Musiime, V. Musoke, P. Ferrier, A. Kitaka, S.B. Odongo, F. Thomason, M.J. Lee, D.Y. Burger, D. Thoofer, N. Snowden, W.